Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Total Non-current Liabilities
All obligations due after more than one year.
Evommune, Inc.NYSE: EVMN
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 96.2% from a year ago
Total non-current liabilities stood at $7.3M at the end of Q1 FY2026, down 96.2% from a year earlier and up 396.1% from the prior quarter.
Context
- Total non-current liabilities amounted to 2.3% of total assets at the end of Q1 FY2026, down 340.9 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -96.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 1.47M USD
- Year-over-year change
- -99.2%
- 2-year CAGR
- -90.2%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.47M | -99.2% |
| FY2024 | 2024-12-31 | 192.31M | +25.6% |
| FY2023 | 2023-12-31 | 153.11M | — |
Total Non-current Liabilities vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's Mar 2026 total non-current liabilities of $7.3M is the 8th highest of the 10 companies compared; the peer median is $71.29M.
- Its year-over-year change of -96.2% is the lowest of 10, against a peer median of -5.9%.
- Total non-current liabilities amounts to 2.3% of total assets for EVMN, versus a peer median of 45.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | Jun 2026 | $1.23B | -5.9% | +71.3% | 45.2% |
| Jun 2026 | $1.17B | +2017.1% | +96.8% | 53.6% | |
| Sep 2026 | $756.7M | +2052.0% | -16.0% | 64.3% | |
| Mar 2026 | $279.76M | +15.0% | +0.0% | 212.9% | |
| Mar 2026 | $71.29M | +22.2% | +8.4% | 55.1% | |
| Mar 2026 | $20.28M | -9.8% | -25.0% | 7.0% | |
| Mar 2026 | $17.44M | -18.0% | -31.1% | 5.9% | |
EVMNEvommune, Inc. | Mar 2026 | $7.3M | -96.2% | — | 2.3% |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $7.23M | -29.7% | -68.3% | 6.8% |
CLYMClimb Bio, Inc. | Mar 2026 | $216K | -32.3% | +16.6% | 0.1% |
| Peer median (excluding EVMN) | $71.29M | -5.9% | +0.0% | 45.2% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.